Boston Scientific Estimates Q3 2024 Net Sales Growth Of Approximately 13%-14% On A Reported And Organic Basis, With Adjusted EPS Of $0.57-$0.59 Versus Consensus Of $0.57
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific estimates Q3 2024 net sales growth of approximately 13%-14% on a reported and organic basis, with adjusted EPS of $0.57-$0.59 versus consensus of $0.57.
July 24, 2024 | 10:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific estimates Q3 2024 net sales growth of 13%-14% and adjusted EPS of $0.57-$0.59, slightly above the consensus of $0.57.
The projected net sales growth and adjusted EPS are positive indicators for Boston Scientific, suggesting strong performance and potential for stock price appreciation. The EPS projection slightly exceeds the consensus, which is likely to be viewed favorably by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100